Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075675 | 1.00 | METAP1 (0.52) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL20284937 | 0.89 | METAP1 (0.50) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL29619166 | 0.89 | METAP1 (0.50) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL23482029 | 0.87 | METAP1 (0.53) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL29619168 | 0.87 | METAP1 (0.53) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL2082187 | 0.87 | METAP1 (0.53) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL28191187 | 0.86 | METAP1 (0.52) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL31561700 | 0.85 | METAP1 (0.51) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL24589410 | 0.85 | METAP1 (0.51) | METAP1NAMPTCYP17A1ATRTDP2 | |
| SCHEMBL31213811 | 0.83 | METAP1 (0.49) | METAP1NAMPTCYP17A1ATRTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METAP1 20/4885NAMPT 1038/4885CYP17A1 2276/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METAP1 20/4885NAMPT 1038/4885CYP17A1 2276/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METAP1 20/4885NAMPT 1038/4885CYP17A1 2276/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | METAP1 20/4885NAMPT 1038/4885CYP17A1 2276/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | METAP1 20/4885NAMPT 1038/4885CYP17A1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.